Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MN-001 in idiopathic pulmonary fibrosis
NCT02503657Phase 2Completed
- Sponsor
- MediciNova, Inc.
- Start
- Mar 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing MN-001/MN-001 with Placebo/MN-001 (2 arms). Primary endpoints: Forced Vital Capacity at 26 weeks, Forced Vital Capacity Percent Predicted at 26 weeks and 1 more. Started Mar 2016; status: completed.
02
Drugs
tipelukast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02503657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503657.